CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0011675: ArrhythmiaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug2660 VitalConnect Vital Sign Patch Wiki 0.58
drug2876 lung ultrasound Wiki 0.58
drug469 COVID-19 antibodies testing Wiki 0.58
drug467 COVID-19 Swab Wiki 0.58
drug464 COVID-19 RT-PCR Wiki 0.33

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D001145 Arrhythmias, Cardiac NIH 1.00
D016171 Torsades de Pointes NIH 0.58
D001919 Bradycardia NIH 0.58
D054537 Atrioventricular Block NIH 0.58
D001281 Atrial Fibrillation NIH 0.58

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0004757 Paroxysmal atrial fibrillation HPO 0.58
HP:0001678 Atrioventricular block HPO 0.58
HP:0001664 Torsade de pointes HPO 0.58
HP:0001662 Bradycardia HPO 0.58

There are 3 clinical trials

Clinical Trials


1 Remote Monitoring in Patients With Coronavirus Disease (COVID-19)

The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.

NCT04350476 COVID-19 Cardiac Arrhythmias Diagnostic Test: VitalConnect Vital Sign Patch
MeSH:Arrhythmias, Cardiac
HPO:Arrhythmia

Primary Outcomes

Description: ac rhythm in patients with COVID-19 infection following treatment/discharge from MSH

Measure: Number of different arrhythmias

Time: 7-14 Days

Description: Temperature of patients with COVID-19 infection following treatment/discharge from MHS

Measure: Temperature

Time: 7-14 Days

Description: Oxygen saturation level in patients with COVID-19 infection following treatment/discharge from MSH

Measure: Oxygen Saturation

Time: 7-14 Days

2 Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)

The objective of the study is to estimate the frequency of cardiac arrhythmias and characterize the mode of death in patients with coronavirus disease (COVID-19). This is a single-center, retrospective/ prospective registry enrolling all COVID-19 positive patients at Mount Sinai Hospital. Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital will be included.

NCT04358029 COVID 19 Cardiac COVID 16 Arrhythmia COVID 19 Death
MeSH:Arrhythmias, Cardiac
HPO:Arrhythmia

Primary Outcomes

Description: To characterize the frequency of cardiac arrhythmias in patients with COVID-19 infection

Measure: Frequency of cardiac arrhythmias

Time: 19 Months

Secondary Outcomes

Description: To characterize the mode of death in patients with COVID-19 infection

Measure: Mode of death

Time: 19 Months

3 COVIDAR - International Registry on Arrhythmias in COVID-19

BACKGROUND AND RATIONALE: There is very limited literature available on the arrhythmia occurrence in the context of an infection by the SARS-CoV2 virus. On the other hand, treatment strategies against the SARS-CoV2 virus may carry a risk of QTc prolongation and pro-arrhythmia/sudden death which may be amplified by concomitant use of other QTc-prolonging drugs and/or ion disbalances. COVIDAR is an international initiative to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, to identify potential modifiable predisposing factors to reduce their incidence and to inform the best arrhythmia management options in this patient population. MAIN OBJECTIVE: To describe the incidence and type of arrhythmic events in the context of the SARS-CoV2 infection. STUDY DESIGN: patient registry (observational). Patients will not undergo any additional investigations. Only data that is generated during routine clinical care will be collected. STUDY POPULATION: Patients admitted to the hospital highly suspected of or with confirmed COVID-19.

NCT04437901 COVID Arrhythmia Torsades de Pointe Caused by Drug Qt Interval, Variation in Atrioventricular Block Atrial Fibrillation Bradyarrhythmia Ventricular Arrythmia
MeSH:Atrial Fibrillation Arrhythmias, Cardiac Atrioventricular Block Bradycardia Torsades de Pointes
HPO:Arrhythmia Atrial fibrillation Atrioventricular block Bradycardia Paroxysmal atrial fibrillation Torsade de pointes

Primary Outcomes

Description: Any arrhythmic event occurring in COVID-19 patients during hospital admission: Monomorphic ventricular tachycardia Polymorphic ventricular tachycardia/Torsades de pointes (non-sustained) Ventricular fibrillation AV-block Severe bradycardia, symptomatic and/or requiring treatment New-onset atrial fibrillation Other

Measure: Arrhythmia

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Secondary Outcomes

Description: Categorical variable collecting the patient's underlying rhythm at baseline, on treatment and in case of arrhythmic adverse events): sinus rhythm, atrial fibrillation/flutter, other

Measure: Electrocardiographic changes - Underlying rhythm

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a categorical (normal, 1st-, 2nd- or 3rd degree AV block) and a continuous (PR duration in ms) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - Atrioventricular conduction

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - QRS duration

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a categorical variable (not present, type 1 or type 2) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - presence of Brugada QRS pattern

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Electrocardiographic changes - QTc duration

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Kalium, magnesium and calcium collected as continuous variables at baseline, on treatment and in case of arrhythmic adverse events). Will be reported as a categorical variable (presence/absence) of electrolyte misbalance

Measure: Laboratory abnormalities - electrolyte misbalance

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Cardiac CK, troponin T and/or troponin I (where available) collected as a continuous variable at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Laboratory abnormalities - cardiac biomarkers

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Creatinine clearance at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Laboratory abnormalities - renal function

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months

Description: Liver enzymes collected at at baseline, on treatment and in case of arrhythmic adverse events)

Measure: Laboratory abnormalities - liver function

Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months


HPO Nodes


HP:0011675: Arrhythmia
Genes 611
SLMAP LIMK1 TTR ELP1 LMNA CPOX ND1 COX1 PTEN CSRP3 LMNA SCN5A SCN1B KCNK3 NF1 RRAS2 ELN CTLA4 KCNH2 RPL5 CACNB2 GATA6 KCNQ1 LMNA RRM2B ATP6 MRPS14 MFAP5 SYNE2 TRNC CLIC2 TSC1 CACNA1C BMP2 GNA11 BANF1 TRPM4 HCCS GLA TRNK TRNL1 ND4 TMEM43 GNB5 DMD POLG2 TNNT2 ERCC8 RAF1 TRDN KCNQ1 LMNA CALM1 FHL1 LRP6 TNNI3 GJA1 HLA-B TRNQ RUNX1 TRNK COX3 KCNQ1 NDUFS2 TTPA CACNA1C HRAS TNNT2 KCNE3 MYBPC3 SYNE1 CACNA1S BSCL2 SCN10A MRAS CALM3 ELN PIK3CA TAB2 SNTA1 ABCC9 CSF2RB TMEM70 COX3 ND4 ACADVL PAX8 SDHA DES TECRL SLC19A2 ABCG8 LMNA DAXX KCNE2 KCND3 PEX1 COQ4 AKAP9 RPS28 CYTB TRPM4 SLC25A20 PSMB8 TCAP FOXC2 DMD RET GLA LAMA2 RPL11 LAMP2 NKX2-5 SLC25A11 DST SCNN1A SCN5A KCNQ1 GALC SEMA3A LMNA FOS TRNQ GPD1L JPH2 RBM20 TSPYL1 HLA-DPB1 TP53 PRKAG2 AGPAT2 PKP2 PPA2 TNNI3 PLN COQ9 TRNS1 ND5 CACNA2D1 TPM1 GTF2IRD1 SDHC PEX16 PPARG SOS2 TRNH PEX11B MYOZ2 PCCB ALG10B EFEMP2 PEX5 MYH7 SDHD MYLK2 RET RFC2 KCNJ2 KCNJ5 LDLR ERCC6 WIPF1 DLST CASQ2 PCCA GJA1 CAV3 CPT1A PEX12 RAF1 GPC4 HNF1A TRNW EP300 GATAD1 SCN5A RYR2 TMEM43 BVES SDHB ND5 PTPN11 LMNA SCN5A ACTC1 CLIP2 PYGM SCNN1G GPX4 SCN4A EMD PEX5 XK CACNA1C WAS FLNC SCN5A ATP6 SCN5A GATA4 HCN4 TMEM70 RPS27 RPS7 CACNA1S ENPP1 TRNS2 MGME1 CAV3 GTPBP3 DMPK UCP2 TNNC1 KCNQ1 GNAI2 CACNA1S PEX19 AKT1 COX1 SRY KCNE1 MYPN MYL2 CREBBP DSC2 ND5 ACADM SDHB HBB SCN2B SOS1 MYH6 RYR1 LMNA PRTN3 SCN1B MYH7 MDH2 GSN CACNA1D ND6 ND6 DNMT3A PPOX GAA CYTB FBP1 SCN4B ELP1 BMP2 TAB2 ND4L TRNL1 HJV HMGCL KCNH2 KCNE1 RPS17 RET MEFV MYL4 LARS2 GPD1L RAF1 TANGO2 DPP6 BRAF CAV1 CPT2 TGFBR2 NR2F2 RYR2 NAA10 CPT1A RPL35A EFEMP2 ABCC6 COX2 RET KCND3 SCNN1A RPL31 RIT1 RPL15 ACTN2 KCNJ18 ACAD9 CPOX CAVIN1 GNAQ MGME1 ND2 MAX RAF1 ACTC1 HADHB SGO1 DSP RPL27 ND6 KIF1B SLC25A4 FLNC TGFB3 TNNI3 SMAD3 TRNL1 PRKAG2 MTO1 GPC3 ND6 KCNJ8 SCNN1B GNB5 ND1 CRELD1 KCNE2 KCNJ2 KCNE1 CBL PRDM16 GLUL RPS24 VHL PGM1 GATA1 GATA5 SDHB SDHAF2 VHL DTNA KCNQ1 CYTB GDAP1 A2ML1 SCN5A SALL4 FHL1 SCNN1A TRNF CACNB2 SCN10A ATRX TOP3A CPT2 HADHA COX7B WIPI2 CLCF1 CPT2 TMEM127 TDP2 CTNNA3 SDHD RPS26 GJA5 COX7B PHYH SCNN1B NKX2-5 CAV3 COX1 HSPG2 COX3 NPPA PEX26 HFE FBLN5 ND4 MYPN RPL26 RPS29 NPPA KCNA5 APOB SDHD SCN1B ND1 KCNH2 SDHD SLC25A20 KCNQ1 GDNF KCNJ18 TTN KCNE2 ECE1 KCNQ1 TRNE SDHC FH SYNE2 TSC2 BMP2 NOS1AP PEX6 TBX3 ABCC9 CALM1 COX3 PEX3 RPS10 TRDN EYA4 USP18 SCN3B HTRA2 CALM1 CIZ1 TBX5 JUP CALM2 RANGRF CASQ2 SCN5A CYTB PKP2 TRNV KCNJ11 TAZ TRDN TAB2 ACADL KCNJ2 TWNK ABCC8 IKZF1 PEX13 CALM3 KCNJ2 AKAP9 SCN9A NRAS MYH7 SNTA1 SCN9A NUP155 POLG EPAS1 SPECC1L SLC2A10 PTPN22 KCNE1 GTPBP3 DMPK NAA10 KYNU POLG2 MYL3 BAZ1B FLAD1 TRNS2 VHL PCSK9 ABCA12 CSF2RA CBL ISCU ASXL1 NDUFB11 PEX2 APRT TGFBR1 FBP1 HLA-DPA1 ANK2 SDHD DSG2 TLL1 CNBP TSHR SCN5A ND4L CAVIN1 SLC12A3 DSP FMO3 VPS33A LDB3 TANGO2 TTN CRLF1 TWNK RPS15A KCNE3 COX2 TRNF HFE GBA GTF2I IFNG EMD LIPT1 CACNA1S KCNJ5 TET2 SCN1B AKAP10 HCN4 MEN1 RASA2 SCN3B KCNE5 CLCNKB BRAT1 PEX6 ND1 ND2 RYR2 LDLRAP1 GJA5 MYH7 RPL18 UQCRFS1 KCNH2 TPM2 SOX10 DNMT3A COL4A1 TSR2 TSPYL1 HLA-B HNF4A LMNA TPM3 KRAS BTNL2 FOXC2 TECRL DNAJC19 TNNI3K PTPN22 SDHB JUP TRDN TRNW ABCG5 GYG1 TMEM127 LMNA CALM1 CASR CAV3 HCN4 ADA2 LZTR1 SRSF2 TRPM4 SLC12A3 PTPN11 ATP6 ND5 CACNA1C CACNA2D1 SMAD3 TMEM43 FBXL4 GPX4 PLN NKX2-5 SLC40A1 PEX10 TBL2 HMBS FHL1 HMBS PEX14 PRKAG2 RYR1 HCCS KYNU RPL35 DES ACADVL MAX SCN5A SCN4B MYPN PEX7 ABCC9 KIF1B MTFMT CALM2 GYG1 TRNS1 SCN2B KIF20A DSP HLA-DRB1 PSAP TNXB NDUFB11 CDH23 RPS19 RRAS JUP CASQ2 ANK2 PHOX2B NDUFB11 ZMPSTE24 CALM2 NEXN SLC19A2 SCNN1G VHL TBX3 CLIC2 TET2 PEX1 GABRA3
Protein Mutations 0